Quintiles is widely known as a leading clinical research organization, having been performing clinical trials for pharma and academic sponsors since it was founded in 1982. Recognizing the importance of precision medicine to the future of drug development, Quintiles staked out an early lead in the space through its acquisition of Expression Analysis (EA) in 2013. Nature talked withKellie Yarnell, EA’s VP of Genomic Operations, about the importance of integrating genomics with clinical development. With an academic background in biochemistry and a career focused on genomics and business development, she recently took over as global head of EA.
Article April 10, 2015